Assessment cycle 2026 Q1 — page 2
Documents ratified in the 2026 Q1 assessment cycle, which ran from 1 January 2026 to 31 March 2026 and was ratified on 18 March 2026.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
02 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over 68 weeks or longer. The Institute holds no reported…
03 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in sleep apnoea over 52 weeks. The Institute holds no reported primary result for this record…
11 Jan 2026 -
Randomised, double-blind, active-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over 72 weeks. The Institute holds no reported primary…
14 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over 76 weeks. The Institute holds no reported primary result for this record and…
19 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over 76 weeks. The Institute holds no reported primary result…
26 Jun 2026 -
Event-driven cardiovascular outcome trial, phase 3 study of Survodutide in cardiovascular and obesity over event-driven. The Institute holds no reported primary result…
11 Jul 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over 42 weeks. The Institute holds no reported primary result for this record and…
01 Feb 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over 52 weeks. The Institute holds no reported primary result for…
06 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over 72 weeks. The Institute holds no reported primary result for this…
27 Feb 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low05 May 2026 -
Single-arm open-label, phase 3 study of Retatrutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low09 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low22 Mar 2026 -
Single-arm open-label, phase 3 study of Retatrutide in sleep apnoea over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low18 Mar 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low24 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low17 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Feb 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low03 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low13 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Feb 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low26 Feb 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low20 Mar 2026 -
Single-arm open-label, phase 3 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low19 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low19 Jul 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 Feb 2026 -
Randomised crossover, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low10 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low29 Jan 2026 -
Randomised crossover, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low26 Jan 2026 -
Observational, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low02 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low05 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low19 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low17 May 2026
page 2 of 3